Tiotropium Respimat®

DRUG2 trials

Sponsors

Novartis Pharmaceuticals, Boehringer Ingelheim

Conditions

AsthmaPulmonary Disease, Chronic Obstructive

Phase 3

Efficacy of NVA237 (50 μg o.d) Using Tiotropium (5μg μg o.d) as Active Control in COPD Patients.

WithdrawnNCT01837927

Novartis PharmaceuticalsPulmonary Disease, Chronic Obstructive

Start: 2014-04-30End: 2016-04-30Updated: 2016-08-22

Unknown Phase

Impact of Tiotropium Add-on Therapy in Patients With Asthma

CompletedNCT03964220

Boehringer IngelheimAsthma

Start: 2019-03-15End: 2019-09-20Updated: 2020-11-03